Overview

Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a multicentric, open-label,non-randomized concurrent control, 1:1 match,non-inferiority trial that assesses the efficacy and safety of neoadjuvant chemotherapy regimen DC-T and EC-T in breast cancer patients.
Phase:
Phase 4
Details
Lead Sponsor:
Zhejiang University
Collaborators:
First Affiliated Hospital of Wenzhou Medical University
First Affiliated Hospital of Zhejiang University
First People's Hospital of Hangzhou
Hangzhou Hospital of Traditional Chinese Medicine
Jinhua Central Hospital
Ningbo No. 1 Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University
Sir Run Run Shaw Hospital
Women's Hospital School Of Medicine Zhejiang University
Zhejiang Cancer Hospital
Zhejiang Provincial Hospital of TCM
Zhejiang Provincial People's Hospital
Zhejiang Provincial People’s Hospital
Treatments:
Cyclophosphamide
Docetaxel
Doxorubicin
Epirubicin
Liposomal doxorubicin